Metformin combined with thymoquinone (TQ) could increase the level of cleaved poly (ADP-ribose) polymerase (PARP) in primary CLL cells, decrease the level of proliferation regulatory proteins, and inhibit the Akt and NF-kB signaling pathways, suggesting that metformin can be used as a therapeutic strategy for CLL [61]. This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.